Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Bristol-Myers Squibb (NY: BMY )

58.87 +0.64 (+1.10%)
Official Closing Price Updated: 7:00 PM EST, Nov 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Bristol-Myers Squibb

< Previous 1 2
...
22 23 24 25 26 27 28 29 30
...
66 67 Next >
3 No-Brainer Dividend Stocks to Buy in September
Income investors should really like these biopharma stocks with juicy dividends. 
Via The Motley Fool
8 Pharma Stocks Affected by New Drug Price Negotiation Rules
Which companies have the most to lose now that Medicare can negotiate directly with them on the prices of some of the most widely used drugs? 
Via The Motley Fool
How Much Pain Will Lower Medicare Prices Cause for Pharma Stocks?
Pharmaceutical stocks are holding steady as Medicare price negotiations approach, but industry diversification and innovation support future growth prospects. 
Via MarketBeat
Topics Economy
Exposures Interest Rates
Bristol Myers Squibb to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference
From Bristol Myers Squibb
Via Business Wire
(BMY) - Analyzing Bristol-Myers Squibb's Short Interest
Via Benzinga
Bristol-Myers Squibb Unusual Options Activity For August 21
Via Benzinga
3 Undervalued Healthcare Stocks In 2023
These 3 undervalued healthcare stocks in 2023 are attractive today for their attractive valuations and total return potential. 
Via Talk Markets
Biden Administration Vs. Big Pharma: What the Legal Showdown Means for Your Wallet
The Biden administration's move to lower drug prices has prompted a flurry of legal challenges. 
Via Benzinga
What Impact Will Medicare Price Negotiations Have on Big Pharma Stocks?
Investors appear to be yawning for the most part at the latest news on Medicare drug price negotiations. 
Via The Motley Fool
Bristol Myers' Expanded Approval For Anemia Drug, Shows Superior Efficacy Over Concurrent Blood Transfusion
On Monday, the FDA approved Bristol Myers Squibb Co's (NYSE: BMY) Reblozyl (luspatercept-aamt) for anemia without previous erythropoiesis-stimulating agent use (ESA-naïve) in adult patients with very... 
Via Benzinga
Exposures Product Safety
Important Data Ahead, Tesla Turning On Massive Nvidia Cluster, 10 Drugs Name For Price Cuts
To gain an edge, this is what you need to know today. 
Via Benzinga
Check Out What Whales Are Doing With BMY
Via Benzinga
Blockbusters From AbbVie, Merck, Lilly Highlight List Of 10 Drugs Subject To Price Cuts
The Biden administration is planning to negotiate the prices of 10 drugs in 2026. 
Via Investor's Business Daily
Coinbase Global, Bristol-Myers Squibb And 2 Other Stocks Insiders Are Selling
The Nasdaq 100 closed higher by over 100 points on Monday. Investors, meanwhile, focused on some notable insider trades. 
Via Benzinga
U.S. FDA Approves Bristol Myers Squibb’s Reblozyl® (luspatercept-aamt) as First-Line Treatment of Anemia in Adults with Lower-Risk Myelodysplastic Syndromes (MDS) Who May Require Transfusions
From Bristol Myers Squibb
Via Business Wire
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Long-Term Follow-Up Data from Two Phase 3 Studies of CAMZYOS® (mavacamten) Demonstrate Consistent and Durable Response in Patients with Symptomatic Obstructive Hypertrophic Cardiomyopathy (HCM)
From Bristol Myers Squibb
Via Business Wire
A Step Closer To Cheaper Drugs For Americans: Price Negotiation And Its Implications
Some of the most frequently prescribed medications in the U.S. might soon become more affordable. 
Via Benzinga
Is Alexandria Real Estate Equities a Buy?
Great company, attractive valuation, lousy sector. 
Via The Motley Fool
Pharma Giants Unite Against Drug Price Negotiation: AstraZeneca Latest To Challenge The Government
AstraZeneca Plc (NASDAQ: AZN) announced its legal challenge against the U.S. 
Via Benzinga
Retrospective Observational Study Assessing Real-World Clinical Impact of Switching or Continuing Eliquis® or Rivaroxaban Presented at the European Society of Cardiology (ESC) Congress 2023
From Bristol Myers Squibb
Via Business Wire
GRI Bio Is Bringing Hope To Patients With Idiopathic Pulmonary Fibrosis And Lupus
Inflammatory diseases are chronic conditions that involve the abnormal activation of the body's immune system, leading to chronic inflammation in various organs and tissues. Two of these diseases that... 
Via Benzinga
Biotech Breakthroughs: 3 Companies on the Cusp of Major Discoveries
Here are just a few top biotech stocks that may be on the cusp of major, game-changing discoveries, thanks to AI. 
Via InvestorPlace
Bristol Myers Squibb Shares Progress Toward Its Environmental, Social, and Governance Initiatives and Its Health Equity Commitments
From Bristol Myers Squibb
Via Business Wire
3 Sorry Pharma Stocks to Sell in August Before It’s Too Late
Factors in the marketplace caused these companies to underperform, making them some of the top pharma stocks to sell. 
Via InvestorPlace
Bristol Myers Squibb Receives European Commission Approval for Opdivo (nivolumab) as an Adjuvant Treatment for Patients with Completely Resected Stage IIB or IIC Melanoma
From Bristol Myers Squibb
Via Business Wire
Large Cap Biopharmaceuticals Performance 2023 YTD: Mixed Results But Lilly Is A Big Winner
Biotech stocks are in a bear market since the IBB hit $177.37 in 2021 and is down 7.84% over five years. 
Via Talk Markets
Bristol Myers Squibb to Showcase Data Across its Innovative Cardiovascular Portfolio at the European Society of Cardiology Congress 2023
From Bristol Myers Squibb
Via Business Wire
Bristol Myers' Investigational Lung Cancer Candidate Shows High Response Rates
Bristol Myers Squibb & Co (NYSE: BMY) announced updated results from a TRIDENT-1 study, demonstrating that repotrectinib — a next-generation ROS1/TRK tyrosine kinase inhibitor (TKI) — continued to show... 
Via Benzinga
Updated Data from TRIDENT-1 Trial Show Durable Efficacy Benefits with Repotrectinib for Patients with Locally Advanced or Metastatic ROS1-Positive Non-Small Cell Lung Cancer
From Bristol Myers Squibb
Via Business Wire
< Previous 1 2
...
22 23 24 25 26 27 28 29 30
...
66 67 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.